Sepsis Market Opportunity Sepsis is a leading cause of in-hospital mortality with rapid deterioration if untreated, creating a high-value target for IntelliSep. Hospitals and EDs seeking faster triage and earlier intervention represent a sizable addressable market for Cytovale's FDA-cleared test.

Executive Appointments Recent additions to the leadership team in marketing and commercial roles signal a push to scale adoption in U.S. emergency departments. Leverage these leaders to align messaging, marketing programs, and field strategy with hospital procurement cycles.

Commercial Readiness With a transition to a more commercial footing and notable financing, Cytovale is positioned to expand hospital-based deployments and payer discussions. Focus on hospital networks, IDSs, and volume-based contracts for faster ROI demonstrations.

Strategic Collaborations High-profile funding and industry recognition create credibility for partnerships with hospital systems, distributors, and diagnostic integrators. Pursue collaboration opportunities to broaden IntelliSep’s integration into existing lab and ED workflows.

Product Differentiation IntelliSep offers rapid, biomechanical analysis from a standard blood draw in under 10 minutes, enabling early risk stratification for sepsis. Target health systems prioritizing speed, accuracy, and bedside decision support to reduce sepsis mortality and associated costs.